5,000 NHS Patients Will Trial a Bladder Cancer Urine Test

A bladder cancer urine test being studied across the West Midlands has just picked up the kind of endorsement no press release can buy — from a patient in Essington who has been through the disease three times. The BBC carried the story this week, and the Express & Star covered the same patient, describing a three-time survivor throwing their weight behind what the paper called a landmark trial. The pitch is disarmingly simple: fill a pot, instead of having a camera passed up into your bladder.

Behind that one voice sits a much larger programme. Nonacus, the diagnostics company behind the Galeas Bladder test, is putting £5m into two bladder cancer diagnostic trials covering 5,000 patients at seven NHS trusts, working alongside Cancer Research UK. New Cross Hospital in Wolverhampton — a few miles down the road from Essington — is among the sites listed as recruiting. The company has said more than 100,000 UK patients could eventually benefit.

That matters most to people already in the system. Bladder cancer has an unusually long tail: many people diagnosed with the non-muscle-invasive form are cleared of their tumour, then spend years on a surveillance schedule, returning again and again for a look inside. It is that repeat cycle, not the first diagnosis, that eats up clinic slots and wears patients down.

What the Bladder Cancer Urine Test Actually Looks For

A cystoscopy is a physical inspection. A thin scope goes in through the urethra and a urologist looks for anything growing on the bladder lining. A urine test works the other way round — it hunts for the traces a tumour leaves behind. Tests in this class, including the UroMark and Xpert Bladder Cancer tests, look for cancer DNA or genetic markers shed into urine, which a lab can read from a sample posted or dropped off rather than a procedure booked in a hospital.

The practical difference is time and dignity. A sample needs no anaesthetic, no theatre list, no recovery, and no one has to take a day off work for it. Nonacus argues the approach frees up hospital capacity and gets results back faster, which is exactly the pressure point in NHS urology, where suspected-cancer referrals compete with routine follow-up for the same scope lists.

Why the Camera Is So Hard to Give Up

If a urine sample is cheaper, kinder and quicker, the obvious question is why the scope is still standard. The answer is that a surveillance test carries an asymmetric risk — a miss is not an inconvenience, it is a tumour left growing for months.

The Discomfort Patients Rarely Mention

Published research on office cystoscopy makes uncomfortable reading. Roughly half of patients report moderate to severe discomfort during the procedure, and close to 80% describe anxiety around it as a problem in itself. Reported side effects include pain on passing urine in about half of cases, bleeding in around one in five, and infection in roughly one in twenty. Multiply that by a decade of check-ups and the case for an alternative writes itself.

The Tumour a Test Must Never Miss

Urine markers perform well where it counts most — they are good at ruling out high-grade disease, which is the aggressive kind. But specialists reviewing the evidence still classify them as add-ons rather than replacements. The debate is live: a session at the European Association of Urology congress this year was billed around whether it is time to ditch the scope. The honest answer today is not yet, and that is precisely what these trials exist to settle.

Who Is Taking Part, and What It Involves

The design is deliberately cautious. Participants are people already under investigation for possible bladder cancer who are due a standard cystoscopy and biopsy anyway. They give a urine sample alongside it. Nobody in the trial gives up their scope — the sample is scored against what the camera and the pathologist find, which is the only way to prove a test is safe enough to take over one day.

How This Compares With the American Version

The United States is running a different experiment. The Replace Cysto trial, which opened in late 2023, randomises 240 people with low-grade, intermediate-risk disease to either alternate urine testing with cystoscopy or stick with frequent scopes. Its headline measure is not accuracy but quality of life. So the two efforts answer different halves of the same question: the American trial asks whether swapping actually feels better, while the West Midlands programme, at more than twenty times the size, asks whether the swap is safe in the first place.

What Patients in the Midlands Should Watch For

Worth keeping the timeline in mind. The West Midlands investment was announced in August 2025, and patient stories like this one are only now emerging; trial results, regulatory sign-off and a change to routine NHS practice are years apart, not months. Nonacus chief executive Jeff Bousfield framed the money as a vote of confidence in the region:

Our investment reaffirms the West Midlands as a leading region for trialing new and life-saving innovations and reflects our confidence in the Mayor's focus on health tech for better patient care.

Until the evidence lands, the practical advice has not changed. Blood in your urine — even once, even painless, even if it clears up — is a see-your-GP-this-week symptom, not a wait-and-see one. If you are already on bladder surveillance, keep the cystoscopy appointments you have, and ask your urology team whether your trust is one of the seven recruiting; joining costs you a sample and nothing else. The scope is not going anywhere this year, but the Essington patient's point stands: someone has to go through it first for it to go away for everyone later.